drugset
drugset / Trial / NCT03516591

A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes

NCT03516591 ↗

Phase 1 Completed 14 enrolled Amphivena Therapeutics, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

An open label, Phase 1, study of AMV564 as monotherapy to assess the safety and efficacy in patients with Myelodysplastic Syndromes

Timeline

Start
2018-06-22
Primary completion
2020-07-31
Completion
2020-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AMV564 Protein / enzyme biologic — Intravenous

Indications

myelodysplastic syndrome